+1,275.5%
TQQQ vs MRNA
+554.4%
+721.1%
-81.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.6% | +5.4% | -2.8% | +1.8% |
| 7D | -1.9% | -1.1% | -0.8% | -1.8% |
| 30D | -4.9% | +126.1% | -131.0% | -26.8% |
| 3M | -6.4% | +190.0% | -196.4% | -33.3% |
| 6M | +44.4% | +157.2% | -112.8% | +6.1% |
| YTD | +35.2% | +388.2% | -353.0% | -16.6% |
| 1Y | +49.5% | +467.0% | -417.5% | -12.4% |
| 3Y | +250.7% | +36.1% | +214.6% | +170.4% |
| 5Y | +104.7% | -68.0% | +172.7% | +91.8% |
| All | +1,275.5% | +554.4% | +721.1% | +750.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling